Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 Oct 29, 2025 07:00AM
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences Apr 8, 2024 08:00AM
Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines Jan 5, 2024 10:00AM
Flagship Pioneering Launches Pioneering Intelligence Nov 1, 2023 10:30AM
Invaio achieves first registration for citrus greening solution featuring Trecise™ technology Aug 29, 2023 09:00AM
View Older Stories

May 16, 2023 06:00AM Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
Aug 16, 2022 07:00AM Senda Biosciences Announces Close of $123 Million Series C Financing
Feb 15, 2022 10:05AM INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT
Jan 26, 2022 09:31AM Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology
Nov 10, 2021 02:00AM Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection
Oct 13, 2021 10:11AM Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
Aug 30, 2021 06:30AM Laronde Attracts $440M in First External Financing to Further Advance Endless RNA™ Platform
Feb 7, 2019 09:05AM Seres Therapeutics (MCRB) Reports Corporate Changes to Focus on Advancing Clinical Assets
Feb 7, 2019 09:00AM Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets
Jan 15, 2019 07:04AM Seres Therapeutics (MCRB) announces appointment of Eric D. Shaff as President and CEO
Jan 15, 2019 07:00AM Seres Therapeutics Announces Chief Executive Officer Transition
Jan 3, 2019 07:04AM Seres Therapeutics (MCRB) Enrolled First Patient for Phase 2B Trial of SER-287
Jan 3, 2019 07:00AM Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
Nov 9, 2018 07:00AM Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
Nov 8, 2018 07:00AM Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
Nov 5, 2018 07:00AM Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018
Oct 22, 2018 07:00AM Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical Officer
Oct 3, 2018 07:00AM Seres Therapeutics to Present New Data Supporting SER-109 Clinical Activity at IDWeek 2018
Sep 4, 2018 07:11AM Seres Therapeutics (MCRB) Appoints Meryl Zausner to Board
Sep 4, 2018 07:00AM Seres Therapeutics Strengthens Board of Directors with Appointment of Meryl Zausner, Experienced Biopharmaceutical Financial Leader
Aug 2, 2018 07:00AM Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates
Jul 25, 2018 04:27PM Seres Therapeutics to Host Second Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on August 2, 2018
Jun 1, 2018 07:00AM Seres Therapeutics to Present at Two Upcoming June Conferences
May 17, 2018 07:00AM Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018
May 9, 2018 07:00AM Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates
May 7, 2018 07:00AM Seres Therapeutics to Host First Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2018
May 4, 2018 07:00AM Seres Therapeutics to Present at Two Upcoming May Conferences
Apr 17, 2018 12:00PM Seres Therapeutics (MCRB) Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at AACR
Apr 17, 2018 12:00PM Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting
Mar 9, 2018 07:00AM Seres Therapeutics to Present at Two Upcoming March Conferences
Mar 8, 2018 07:00AM Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
Mar 2, 2018 07:00AM Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018
Jan 4, 2018 07:00AM Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
Nov 14, 2017 06:00AM Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology
Nov 8, 2017 04:00PM Seres Therapeutics to Participate in Three Upcoming November Conferences
Nov 8, 2017 07:00AM Seres Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Operational Progress
Nov 7, 2017 07:00AM Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate
Nov 2, 2017 07:00AM Seres Therapeutics to Host Third Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2017
Nov 1, 2017 07:00AM Sigilon Therapeutics Appoints Eric Shaff to Board of Directors
Aug 31, 2017 07:05AM Seres Therapeutics to Present at the Baird 2017 Global Healthcare Conference
Aug 3, 2017 07:05AM Seres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress
Aug 2, 2017 07:05AM Seres Therapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference
Jul 27, 2017 07:05AM Seres Therapeutics to Host Second Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2017
Jul 10, 2017 07:05AM Seres Therapeutics (MCRB) Names Willard Dere to Board of Directors
Jul 10, 2017 07:05AM Seres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer
Jun 12, 2017 07:09AM Seres Therapeutics (MCRB) Commences SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection
Jun 12, 2017 07:07AM Seres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection
Jun 6, 2017 04:00PM Seres Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference
Jun 5, 2017 07:09AM Seres Therapeutics (MCRB) Reports Completion of Enrollment for SER-287 Phase 1b Study in Patients with Ulcerative Colitis
Jun 5, 2017 07:07AM Seres Therapeutics Announces Completion of Enrollment for SER-287 Phase 1b Study in Patients with Ulcerative Colitis
View Older Stories